Potassium binding drugs

Potassium binder; nonabsorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium. It increases fecal potassium excretion through binding of potassium in the lumen of the GI tract; binding of potassium reduces the free potassium concentration in the GI lumen, thereby lowering serum potassium level.

Many drugs commonly administered to dialysis patients may cause alterations in serum potassium levels. Digitalis competes with potassium for binding sites on the Na-K ATPase pump, so toxicity is potentiated in the setting of hypokalemia, but serum potassium levels rise because binding of drug prevents potassium from entering cells.

by P van der Meer 2024 Cited by 11To bind or not to bind: potassium-lowering drugs in heart failure Furthermore, as with other potassium binding agents, RLY5016 is also

by GH Kim Cited by 29Potassium binding agents may be useful to maintain the serum potassium Revisiting RAAS blockade in CKD with newer potassium-binding drugs.

Key Characteristics of Old and New Potassium-Binding Agents - Dr. Edgar V. Lerma Potassium Binding

ESC 2024: New potassium binding drugs reviewed. October 2024 Leave a comment Patiromer, a potassium binder approved by the US Food and Drug

Drug Classes; Cardiovascular Agents; Group III antiarrhythmics: Potassium-channel blockers, bind to and block the potassium channels which prolongs repolarization

Many drugs commonly administered to dialysis patients may cause alterations in serum potassium levels. Digitalis competes with potassium for binding sites on the Na-K ATPase pump, so toxicity is potentiated in the setting of hypokalemia, but serum potassium levels rise because binding of drug prevents potassium from entering cells.

Class III drugs are known as potassium channel blockers and comprise amiodarone. Class III drugs bind and block the potassium channels used for repolarization.